CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company, has announced interim results from its Phase 2 trial, indicating a survival benefit for its lead clinical candidate, THIO, in treating advanced non-small cell lung cancer (NSCLC). The trial, THIO-101, is assessing the efficacy of THIO in combination with Regeneron’s immune checkpoint inhibitor cemiplimab (Libtayo®) in patients who have failed two or more standard-of-care therapy regimens.
As of August 1, 2024, 16 patients have surpassed a 12-month survival follow-up, with 9 of these being third-line treatment patients. The interim median survival follow-up for these third-line patients is reported at 10.6 months, which compares favorably to the standard-of-care overall survival of 5.8 months.
MAIA's CEO, Vlad Vitoc, M.D., expressed optimism about the trial's progress, noting that three of the earliest enrolled patients are nearing 17 months of survival. These results suggest that THIO could potentially offer a new treatment option for individuals with advanced NSCLC.
The company previously announced in April 2024 that THIO in combination with cemiplimab showed an overall response rate of 38%, a disease control rate of 88%, and a median progression-free survival of 5.5 months for third-line treatment.
THIO is a first-in-class investigational telomere-targeting agent that induces selective cancer cell death and activates both innate and adaptive immune responses. The ongoing THIO-101 trial aims to evaluate the safety and clinical efficacy of THIO, with overall response rate as the primary endpoint. The treatment has been generally well-tolerated in a heavily pre-treated patient population.
MAIA anticipates releasing full efficacy results from the THIO-101 trial within the current year. The information reported is based on a press release statement from MAIA Biotechnology, Inc.
InvestingPro Insights
As MAIA Biotechnology, Inc. continues to report encouraging results from its Phase 2 trial for THIO, investors are closely monitoring the company's financial health and stock performance. According to recent data from InvestingPro, MAIA holds a market capitalization of $83.2 million. The company's stock has shown a significant return over the last week, with a price total return of 19.18%. This surge in stock value is also reflected in the six-month price total return, which stands at an impressive 161.65%.
InvestingPro Tips indicate that MAIA holds more cash than debt on its balance sheet, which is a positive sign for financial stability. Moreover, the company's liquid assets exceed its short-term obligations, further highlighting its liquidity position. However, it is important to note that analysts do not anticipate the company will be profitable this year, and MAIA is not currently paying a dividend to shareholders. Despite these factors, the company's recent progress in clinical trials could be a catalyst for future growth.
Investors interested in MAIA's detailed financial analysis can find additional InvestingPro Tips, which provide deeper insights into the company's performance and potential. There are 11 more tips listed on InvestingPro for MAIA at https://www.investing.com/pro/MAIA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.